The Serine/Threonine Protein Kinase SIK3 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase SIK3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase SIK3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Gastrointestinal, and Musculoskeletal Disorders which include the indications Solid Tumor, Triple-Negative Breast Cancer (TNBC), Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Osteoporosis, and Unspecified Musculoskeletal Disorders. It also reviews key players involved in Serine/Threonine Protein Kinase SIK3 targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase SIK3 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 1, 2, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Serine/Threonine Protein Kinase SIK3 overview
Serine/threonine-protein kinase SIK3, or Salt-Inducible Kinase 3, is a member of the AMP-activated protein kinase (AMPK) family, known for its role in cellular energy regulation and various physiological processes. SIK3, specifically, has been implicated in diverse cellular functions, including cell cycle regulation, metabolism, and response to environmental stressors. Under conditions of low energy or cellular stress, SIK3 activity is typically upregulated. It functions as a kinase, phosphorylating target proteins and thereby participating in signaling pathways that govern cellular responses to environmental cues. The kinase activity of SIK3 is modulated by its phosphorylation state, with specific phosphorylation events regulating its enzymatic function. Dysregulation of SIK3 has been observed in certain diseases, including cancer, highlighting its potential significance in pathological conditions.
For a complete picture of Serine/Threonine Protein Kinase SIK3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
